BIOCRYST PHARMACEUTICALS, INC. Proceeds from Issuance of Secured Debt
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Proceeds from Issuance of Secured Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2023-02-27
- BIOCRYST PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2022 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2020 was $119.87M.
| Period end | Proceeds from Issuance of Secured Debt 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-27 |
| 2020-12-31 | $119.87M 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |